Managing atrial fibrillation in the elderly: critical appraisal of dronedarone

Paula Trigo, Gregory W FischerDepartment of Anesthesiology, Mount Sinai School of Medicine, New York, NY, USAAbstract: Atrial fibrillation is the most commonly seen arrhythmia in the geriatric population and is associated with increased cardiovascular morbidity and mortality. Treatment of the elderl...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Trigo P, Fischer GW
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Atrial Fibrillation elderly antiarrhythmia agents amiodarone dronedarone Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/7baeb20230a648d894fa3ec3e3a1d0be
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7baeb20230a648d894fa3ec3e3a1d0be
record_format	dspace
spelling	oai:doaj.org-article:7baeb20230a648d894fa3ec3e3a1d0be2021-12-02T03:49:48ZManaging atrial fibrillation in the elderly: critical appraisal of dronedarone1178-1998https://doaj.org/article/7baeb20230a648d894fa3ec3e3a1d0be2011-12-01T00:00:00Zhttps://www.dovepress.com/managing-atrial-fibrillation-in-the-elderly-critical-appraisal-of-dron-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Paula Trigo, Gregory W FischerDepartment of Anesthesiology, Mount Sinai School of Medicine, New York, NY, USAAbstract: Atrial fibrillation is the most commonly seen arrhythmia in the geriatric population and is associated with increased cardiovascular morbidity and mortality. Treatment of the elderly with atrial fibrillation remains challenging for physicians, because this unique subpopulation is characterized by multiple comorbidities requiring chronic use of numerous medications, which can potentially lead to severe drug interactions. Furthermore, age-related changes in the cardiovascular system as well as other physiological changes result in altered drug pharmacokinetics. Dronedarone is a new drug recently approved for the treatment of arrhythmias, such as atrial fibrillation and/or atrial flutter. Dronedarone is a benzofuran amiodarone analog which lacks the iodine moiety and contains a methane sulfonyl group that decreases its lipophilicity. These differences in chemical structure are responsible for making dronedarone less toxic than amiodarone which, in turn, results in fewer side effects. Adverse events for dronedarone include gastrointestinal side effects and rash. No dosage adjustments are required for patients with renal impairment. However, the use of dronedarone is contraindicated in the presence of severe hepatic dysfunction.Keywords: atrial fibrillation, elderly, antiarrhythmic agents, amiodarone, dronedaroneTrigo PFischer GWDove Medical PressarticleAtrial Fibrillationelderlyantiarrhythmia agentsamiodaronedronedaroneGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 7, Pp 1-13 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Atrial Fibrillation elderly antiarrhythmia agents amiodarone dronedarone Geriatrics RC952-954.6
spellingShingle	Atrial Fibrillation elderly antiarrhythmia agents amiodarone dronedarone Geriatrics RC952-954.6 Trigo P Fischer GW Managing atrial fibrillation in the elderly: critical appraisal of dronedarone
description	Paula Trigo, Gregory W FischerDepartment of Anesthesiology, Mount Sinai School of Medicine, New York, NY, USAAbstract: Atrial fibrillation is the most commonly seen arrhythmia in the geriatric population and is associated with increased cardiovascular morbidity and mortality. Treatment of the elderly with atrial fibrillation remains challenging for physicians, because this unique subpopulation is characterized by multiple comorbidities requiring chronic use of numerous medications, which can potentially lead to severe drug interactions. Furthermore, age-related changes in the cardiovascular system as well as other physiological changes result in altered drug pharmacokinetics. Dronedarone is a new drug recently approved for the treatment of arrhythmias, such as atrial fibrillation and/or atrial flutter. Dronedarone is a benzofuran amiodarone analog which lacks the iodine moiety and contains a methane sulfonyl group that decreases its lipophilicity. These differences in chemical structure are responsible for making dronedarone less toxic than amiodarone which, in turn, results in fewer side effects. Adverse events for dronedarone include gastrointestinal side effects and rash. No dosage adjustments are required for patients with renal impairment. However, the use of dronedarone is contraindicated in the presence of severe hepatic dysfunction.Keywords: atrial fibrillation, elderly, antiarrhythmic agents, amiodarone, dronedarone
format	article
author	Trigo P Fischer GW
author_facet	Trigo P Fischer GW
author_sort	Trigo P
title	Managing atrial fibrillation in the elderly: critical appraisal of dronedarone
title_short	Managing atrial fibrillation in the elderly: critical appraisal of dronedarone
title_full	Managing atrial fibrillation in the elderly: critical appraisal of dronedarone
title_fullStr	Managing atrial fibrillation in the elderly: critical appraisal of dronedarone
title_full_unstemmed	Managing atrial fibrillation in the elderly: critical appraisal of dronedarone
title_sort	managing atrial fibrillation in the elderly: critical appraisal of dronedarone
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/7baeb20230a648d894fa3ec3e3a1d0be
work_keys_str_mv	AT trigop managingatrialfibrillationintheelderlycriticalappraisalofdronedarone AT fischergw managingatrialfibrillationintheelderlycriticalappraisalofdronedarone
_version_	1718401604409884672

Managing atrial fibrillation in the elderly: critical appraisal of dronedarone

Ejemplares similares